Two students from the University of Kentucky College of Pharmacy and the University of Maryland Baltimore School of Pharmacy, report on their summer internship at USP sharing their experiences, lessons learned and hopes for a bright future career impacting public health.
Assurances of safety and effectiveness play an important role in instilling confidence among healthcare providers in any new class of medicines. Those assurances include knowing that mandatory public standards for quality and naming have been adhered to in the manufacture of medicines. Find out what this means for top selling biologics in the U.S.
Consumer Reports’ recent exploration into American dietary supplement popularity and limited regulatory oversight reveals dangers to avoid and tips to guide your supplement choices. Among the publication’s recommendations is to look for the USP Verified mark. Learn more.
In the past three decades, an increasingly globalized medical marketplace has helped improve patient access to new medicines. Sadly, it has also provided an opportunity for more substandard, adulterated, and counterfeit medical products. This article explains the evolving role of the ICH in helping to tackle this problem through harmonization, and how USP is linked to the effort.
Dr. Maya Guncheva, a USP visiting scientist from Institute of Organic Chemistry, Centre of Phytochemistry at the Bulgarian Academy of Sciences provides a brief account of her research interests, what brought her from Bulgaria to Rockville, and the highlights of her experience at USP.
Over the past three decades, generic medicines have significantly increased patient access to quality treatment, while lowering healthcare costs in the United States. Learn how a new class of prescription drugs knows as biosimilars, offers the same hope of increased access and reduced costs.
The 69th World Health Assembly, took place in Geneva on May 23 – 28, 2016, and USP was honored to co-host a high level discussion on global public health and the SDGs (Sustainable Development Goals). This article captures parts of the conversation that took place not only in Geneva but via social media as well.
In LMICs, the availability of medicines manufactured locally that do not meet quality standards is a leading cause of treatment failure and adverse events in patients and is undermining public health interventions. But where do things go wrong during pharmaceutical manufacturing in LMICs that give rise to this problem? Learn more.